Head and neck cancer is a broad term for several types of cancers that include the mouth (oral cavity), throat (pharynx), voice box (larynx), sinuses and nose cavity, and salivary glands. Head and ...

RAIPUR: The annual Chhattisgarh Cancer Conclave held at the Balco Medical Centre (BMC) in Nava Raipur featured live surgical ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

This guide for newly diagnosed patients provides key information to help you understand your options and have informed ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain head and neck cancers from returning. Continuous use of Keytruda—both ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

What Are the Different Types of Oral Cancer Surgery? Oral cancer surgery refers to a group of procedures with different jobs: removing cancer, rebuilding areas affected by treatment, or restoring key ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes ...

Keytruda is approved for resectable locally advanced head and neck squamous cell carcinoma with PD-L1 expression, marking a significant advancement in treatment options. The KEYNOTE-689 trial showed a ...

Keytruda reduced the risk of recurrence, progression, or death by 30% vs. standard of care in HNSCC patients. Median event-free survival was 59.7 months with Keytruda vs. 29.6 months with standard ...

Adding neoadjuvant and adjuvant pembrolizumab to the standard of care significantly improved event-free survival in patients with previously untreated, locally advanced head and neck squamous cell ...